Refine
Year of publication
Document Type
- Article (144)
- Conference Proceeding (3)
Has Fulltext
- yes (147)
Is part of the Bibliography
- no (147) (remove)
Keywords
- Cirrhosis (7)
- Antiviral therapy (6)
- Hepatocellular carcinoma (6)
- Liver diseases (6)
- cirrhosis (6)
- hepatitis C virus (5)
- Hepatitis C virus (4)
- liver transplantation (4)
- ACLF (3)
- Chronic hepatitis C (3)
- DAA (3)
- HCC (3)
- acute-on-chronic liver failure (3)
- direct-acting antivirals (3)
- hepatitis C (3)
- liver cirrhosis (3)
- portal hypertension (3)
- Cancer treatment (2)
- Cytoskeletal proteins (2)
- Diabetes mellitus (2)
- Directly acting antiviral agent (2)
- Endoscopy (2)
- HBV (2)
- HCV (2)
- HIV (2)
- Hepatitis (2)
- Immunology (2)
- Inflammation (2)
- Liver cirrhosis (2)
- Liver fibrosis (2)
- Liver transplantation (2)
- Mortality (2)
- NASH (2)
- Ribavirin (2)
- SPTAN1 (2)
- SVR (2)
- Viral load (2)
- ascites (2)
- biliary stricture (2)
- chemotherapy (2)
- co-infection (2)
- fatigue (2)
- inflammation (2)
- insulin resistance (2)
- molecular dynamics (2)
- multidrug resistance (2)
- overall survival (2)
- resistance mutation (2)
- serine protease (NS3-4A) (2)
- transient elastography (2)
- AGC kinase (1)
- APRI (1)
- ARA (1)
- Adeno associated virus (1)
- Adenylyl cyclase (1)
- Alcoholic liver disease (1)
- All oral (1)
- All-oral therapy (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antiviral treatment (1)
- Antivirale Therapie (1)
- Ascites (1)
- Aurora (1)
- B-cell (1)
- BNT162b2 (1)
- Bacterial abundance (1)
- Biliary physiology (1)
- Biochemistry (1)
- Blood (1)
- Blood plasma (1)
- Breast tumors (1)
- Burden of disease (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COVID-19 vaccination (1)
- CT (1)
- Caco-2 cells (1)
- Cancer (1)
- Cancer chemotherapy (1)
- Capnography (1)
- Cardiovascular disease (1)
- Case report (1)
- Cell binding (1)
- Cell motility (1)
- Cell staining (1)
- Cellular (1)
- Chronic Hepatitis C (1)
- Chronic hepatitis (1)
- Clinical efficacy (1)
- Colorectal cancer (1)
- Computed axial tomography (1)
- DNA methylation (1)
- DNA mismatch repair (1)
- Death rates (1)
- Digestive system (1)
- Digestive system procedures (1)
- Direct-acting antiviral agents (DAAs) (1)
- Direct-acting antivirals (1)
- Discovery (1)
- Drug (1)
- EQ-5D (1)
- ESBL (1)
- Early goal-directed therapy (1)
- Eicosanoids (1)
- Endocrine cancer (1)
- Enterobacteriaceae (1)
- Etiology (1)
- FIB-4 (1)
- FSS (1)
- Fatty acids (1)
- Fatty liver (1)
- Fibrosis (1)
- Fibrotest (1)
- Flow cytometry (1)
- GSK2334470 (1)
- GSK3α (1)
- GSK3β (1)
- Gastric cancer (1)
- Gastroenterology (1)
- Gastrointestinal tract (1)
- Gene therapy (1)
- Genetics (1)
- Genome-wide association study (1)
- Genomic medicine (1)
- HBV reactivation (1)
- HCV treatment (1)
- Health care resource utilization (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatotoxicity (1)
- Hispanic people (1)
- Host-targeting agents (HTAs) (1)
- Hypoxia (1)
- IgG4-related disease (1)
- Immune complex vasculitis (1)
- Immune suppression (1)
- Immunohistochemistry techniques (1)
- Indeterminate biliary stricture (1)
- Individualized therapy (1)
- Infection (1)
- Infections (1)
- Infectious disease (1)
- Infectious disease epidemiology (1)
- Integrated Pulmonary Index (1)
- Intensive care unit (1)
- Interferon (1)
- Interferon-free (1)
- Interferon-free HCV treatment (1)
- Interferon-α (1)
- Interferon-λ, (1)
- Interferonfrei (1)
- Interleukin-22 (1)
- Interventional oncological treatment (1)
- Intestinal neoplasms (1)
- Kupffer cells (1)
- Laser interstitial thermal therapy (1)
- Liver (1)
- Liver cancer (1)
- Liver enzymes (1)
- Liver-related complications (1)
- Lymphoma (1)
- MELD (1)
- MLH1 (1)
- MRP4 (1)
- Macrophages (1)
- Medical education (1)
- Membrane staining (1)
- Metabolic syndrome (1)
- Metastasis (1)
- Metastatic tumors (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Microwave ablation (1)
- Molecular biology (1)
- Monitoring (1)
- Mouse models (1)
- Multidrug resistance (1)
- Multidrug-resistance (1)
- Multidrug-resistant organisms (1)
- NAFLD (1)
- NS3-4A protease inhibitor (1)
- NS3/4A protease inhibitors (PI) (1)
- NS5A inhibitors (1)
- NS5B polymerase inhibitor (1)
- Negative staining (1)
- Neuroendocrine cancer (1)
- Next-generation sequencing (1)
- Non-Hodgkin lymphoma (1)
- Non-nucleoside polymerase inhibitors (NNI) (1)
- Null responder (1)
- Obesity (1)
- PCR (1)
- PDK1 (1)
- PIF pocket (1)
- PKA (1)
- PROMISE (1)
- Pathogenesis (1)
- Percutaneous endoscopic gastrostomy (1)
- Personal medicine (1)
- Platelets (1)
- Portal hypertension (1)
- Portal veins (1)
- Primary sclerosing cholangitis (1)
- Prostaglandin (1)
- Protease inhibitor therapy (1)
- Quinolones (1)
- Radiation exposure (1)
- Regression analysis (1)
- SKI II (1)
- SW480 cells (1)
- Safety (1)
- Salmonella choleraesuis (1)
- Sarcopenia (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Sepsis-bundle (1)
- Single nucleotide polymorphism (1)
- Specimen preparation and treatment (1)
- Sphingolipids (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival (1)
- Sustained virological response (1)
- TACE (1)
- TMC435 (1)
- Thrombosis (1)
- Thromboxane (1)
- Transarterial chemoembolization (1)
- Transferases (1)
- Transient elastography (1)
- Tumor obstruction (1)
- Type three hypersensitivity (1)
- VRE (1)
- Veins (1)
- Vitamin D (1)
- Vitamin D deficiency (1)
- acoustic radiation force impulse (1)
- acoustic radiation force impulse imaging (1)
- acute decompensation (1)
- adaptation (1)
- adenosine (1)
- adenosine receptors (1)
- alcoholic hepatitis (1)
- allosteric regulation (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-EGFR therapy (1)
- antibiotic therapy (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- arachidonic acid (1)
- bacterial translocation (1)
- bevacizumab (1)
- bile duct stenosis (1)
- biomarker (1)
- cAMP (1)
- cART (1)
- carbapenem resistance (1)
- chemorefractory metastatic colorectal cancer (1)
- cholangiocarcinoma (1)
- chronic hepatitis C (1)
- chronic viral hepatitis (1)
- colorectal cancer (1)
- combination (1)
- computed tomography (1)
- core expression (1)
- critical care unit (1)
- critical ill patients (1)
- cytokines (1)
- cytoskeleton (1)
- death rates (1)
- decompensated liver cirrhosis (1)
- dihydroceramide (1)
- direct antiviral (1)
- direct antiviral agents (1)
- direct-acting antiviral (DAA) treatment (1)
- direct-acting antivirals (DAAs) (1)
- directly acting antiviral agents (1)
- double-pigtail stents (1)
- drug interaction (1)
- drug resistance (1)
- eNPP2 (1)
- elderly (1)
- endoscopic retrograde cholangiography (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- eosinophilic cholangitis (1)
- epidemiology (1)
- evolution (1)
- exosomes (1)
- fibrosis (1)
- fibrotest (1)
- first-line chemotherapy (1)
- fumonisin B1 (1)
- genotype G (1)
- graft rejection (1)
- health related quality of life (1)
- hemophilia (1)
- hepatic fibrosis (1)
- hepatitis (1)
- hepatitis B (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- hepatitis E virus (1)
- hepatitis c (1)
- hepatocellular carcinoma (1)
- hospital admission (1)
- host-targeting antivirals (1)
- immune escape (1)
- immunity (1)
- immunohistochemistry (1)
- infection control (1)
- innate immunity (1)
- interferon (1)
- interferon-free (1)
- interferon-free antiviral treatment (1)
- interferons (1)
- intrahepatic cholangiocarcinoma (1)
- in vivo (1)
- ischemic type biliary lesions (1)
- lipoxin A4 (1)
- liver (1)
- liver fibrosis (1)
- liver immunology (1)
- long-term follow-up (1)
- macrophages (1)
- male (1)
- mechanical ventilation (1)
- medical risk factors (1)
- metastasis (1)
- metastatic colorectal cancer (1)
- miR-122 (1)
- microsatellite instability (1)
- mitochondrial antiviral signaling protein (MAVS) (1)
- molecular adaptation (1)
- molecular biology (1)
- mortality (1)
- non-invasive fibrosis assessment (1)
- omega-3 fatty acids (1)
- organ dysfunction (1)
- organ failure (1)
- orthopic liver transplantation (1)
- patient-reported outcomes (1)
- peg-interferon lambda (1)
- peginterferon (1)
- peginterferon-α (1)
- perioperative mortality (1)
- phylogenetic analysis (1)
- platelet count (1)
- point shear wave elastography (1)
- prevalence (1)
- primary sclerosing cholangitis (1)
- protease inhibitor (1)
- protein evolution (1)
- protein folding (1)
- protein kinase (1)
- pseudomonas aeruginosa (1)
- pulmonary failure (1)
- re-exposure (1)
- rechallenge (1)
- recurrent cholangitis (1)
- reintroduction (1)
- replicative fitness (1)
- resistance-associated substitutions (RAS) (1)
- resolution of inflammation (1)
- respiratory failure (1)
- ribavirin (1)
- screening routine (1)
- sepsis (1)
- short-course antibiotic therapy (1)
- signature (1)
- simeprevir (1)
- small compounds (1)
- sofosbuvir (1)
- sorafenib (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- spectrin (1)
- sphingolipid (1)
- sphingolipids (1)
- stent patency (1)
- structure constraints (1)
- thrombocytopenia (1)
- thrombocytosis (1)
- transmission (1)
- treatment (1)
- triple therapy (1)
- velpatasvir (1)
- viral fitness (1)
- voxilaprevir (1)
- whole-genome sequencing (1)
- work productivity (1)
Institute
- Medizin (147) (remove)
Einleitung: Am 16.12.06 wurde im Eurotransplant-Gebiet der MELD-Score (MELD) als Allokationsbasis zur Lebertransplantation (OLT) eingeführt. Ziel ist eine Reduktion der Sterblichkeit auf der Warteliste. Material und Methoden: 100 Patienten wurden in die prospektive Analyse der MELD-Allokation vom 16.12.06 bis 15.09.07 einbezogen. Ergebnisse: Aktuell warten 68 Pat., 28 Pat. wurden transplantiert, 4 Pat. sind auf der Warteliste (WL) verstorben (4%). Der mittlere MELD auf der WL beträgt 17,2 +/- 5,2 (7-28). Bei 12 Pat. liegt eine Standard-exception (SE) (n=10 HCC, n=2 metabolische Erkrankung) mit einem Match-MELD von 25,6 +/-2,06 vor (24-28). Die Todesursachen der vier auf der WL verstorbenen Pat. waren eine akute Varizenblutung (MELD 9), zwei kardiale Versagen (MELD 13, 18) und eine MRSA-Sepsis (MELD 29, NT-Status). Die 28 transplantierten Pat. hatte zum Zeitpunkt der Transplantation einen mittleren MELD von 27,66 +/- 5,1 Punkten (21 bis 40). 20 Pat. wurden aufgrund des Labor-MELD (28,4 +/- 5,3, 24-40) transplantiert, wobei 7 Pat. einen MELD über 30 aufwiesen. Die Wartezeit lag bei 11,55 +/- 5,3 Tagen. 8 Pat. erhielten bei SE bei HCC (MELD 24 +/- 0, 24) ein Organ nach einer Wartezeit von 320 +/- 9,7 Tagen. Aktuell leben 23 der 28 transplantierten Pat. Bei zwei verstorbenen Pat. war die Todesursache ein kardiales Versagen, bei zwei Patienten eine primäre Non-Funktion sowie ein septisches Multiorganversagen. Schlussfolgerung: Während der ersten Monate der MELD Allokation lag die Letalität auf der WL in unserem Zentrum bei 4%. Patienten mit einem mittleren MELD über 27 erhielten Organangebote und konnten nach kurzer Wartezeit transplantiert werden.
Aim: To compare clinical success and complications of uncovered self-expanding metal stents (SEMS) vs covered SEMS (cSEMS) in obstruction of the small bowel.
Methods: Technical success, complications and outcome of endoscopic SEMS or cSEMS placement in tumor related obstruction of the duodenum or jejunum were retrospectively assessed. The primary end points were rates of stent migration and overgrowth. Secondary end points were the effect of concomitant biliary drainage on migration rate and overall survival. The data was analyzed according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.
Results: Thirty-two SEMS were implanted in 20 patients. In all patients, endoscopic stent implantation was successful. Stent migration was observed in 9 of 16 cSEMS (56%) in comparison to 0/16 SEMS (0%) implantations (P = 0.002). Stent overgrowth did not significantly differ between the two stent types (SEMS: 3/16, 19%; cSEMS: 2/16, 13%). One cSEMS dislodged and had to be recovered from the jejunum by way of laparotomy. Time until migration between SEMS and cSEMS in patients with and without concomitant biliary stents did not significantly differ (HR = 1.530, 95%CI 0.731-6.306; P = 0.556). The mean follow-up was 57 ± 71 d (range: 1-275 d).
Conclusion: SEMS and cSEMS placement is safe in small bowel tumor obstruction. However, cSEMS is accompanied with a high rate of migration in comparison to uncovered SEMS.
Background/aims: Hepatocellular carcinoma (HCC) is a leading indication for liver transplantation (LT) worldwide. Early identification of patients at risk for HCC recurrence is of paramount importance since early treatment of recurrent HCC after LT may be associated with increased survival. We evaluated incidence of and predictors for HCC recurrence, with a focus on the course of AFP levels.
Methods: We performed a retrospective, single-center study of 99 HCC patients who underwent LT between January 28th, 1997 and May 11th, 2016. A multi-stage proportional hazards model with three stages was used to evaluate potential predictive markers, both by univariate and multivariable analysis, for influences on 1) recurrence after transplantation, 2) mortality without HCC recurrence, and 3) mortality after recurrence.
Results: 19/99 HCC patients showed recurrence after LT. Waiting time was not associated with overall HCC recurrence (HR = 1, p = 0.979). Similarly, waiting time did not affect mortality in LT recipients both with (HR = 0.97, p = 0.282) or without (HR = 0.99, p = 0.685) HCC recurrence. Log10-transformed AFP values at the time of LT (HR 1.75, p = 0.023) as well as after LT (HR 2.07, p = 0.037) were significantly associated with recurrence. Median survival in patients with a ratio (AFP at recurrence divided by AFP 3 months before recurrence) of 0.5 was greater than 70 months, as compared to a median of only 8 months in patients with a ratio of 5.
Conclusion: A rise in AFP levels rather than an absolute threshold could help to identify patients at short-term risk for HCC recurrence post LT, which may allow intensification of the surveillance strategy on an individualized basis.
Erratum for: Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells.Journal of biological chemistry, 2002 Nov 15;277(46):43623-30. doi: 10.1074/jbc.M203926200. Epub 2002 Sep 5.
MutLα is essential for human DNA mismatch repair (MMR). It harbors a latent endonuclease, is responsible for recruitment of process associated proteins and is relevant for strand discrimination. Recently, we demonstrated that the MMR function of MutLα is regulated by phosphorylation of MLH1 at serine (S) 477. In the current study, we focused on S87 located in the ATPase domain of MLH1 and on S446, S456 and S477 located in its linker region. We analysed the phosphorylation-dependent impact of these amino acids on DNA binding, MMR ability and thermal stability of MutLα. We were able to demonstrate that phosphorylation at S87 of MLH1 inhibits DNA binding of MutLα. In addition, we detected that its MMR function seems to be regulated predominantly via phosphorylation of serines in the linker domain, which are also partially involved in the regulation of DNA binding. Furthermore, we found that the thermal stability of MutLα decreased in relation to its phosphorylation status implying that complete phosphorylation might lead to instability and degradation of MLH1. In summary, we showed here, for the first time, a phosphorylation-dependent regulation of DNA binding of MutLα and hypothesized that this might significantly impact its functional regulation during MMR in vivo.
Recent genome-wide association studies (GWAS) have identified genetic variations near the IL28B gene which are strongly associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. Protective IL28B variations are strongly associated with on-treatment viral kinetics and approximately 2-fold increased sustained virologic response (SVR) rates in HCV genotype 1 and 4 patients. In HCV genotype 1 patients, IL28B variations were shown to be the strongest pre-treatment predictor of virologic response. In the treatment of HCV genotype 2 and 3 infected patients, IL28B variations play only a minor role. Preliminary data indicate that IL28B variations are also associated with treatment outcome of regimens, including directly acting antiviral (DAA) agents, though their impact seems to be attenuated compared to standard treatment. Here, we review these important findings and discuss possible implications for clinical decision making in the treatment of HCV infection.
Ribavirin in combination with peginterferon alfa shows strong clinical efficacy against chronic hepatitis C, and is now established as the standard of care. However, the precise role of ribavirin is still being defined, suggesting that optimal ribavirin dose should be maintained over the whole treatment period. Ribavirin dosage varies by bodyweight for genotype 1 disease (1000 mg/day in patients ⩽75 kg and 1200 mg/day in patients >75 kg), whereas 800 mg/day is sufficient to ensure optimal response in all genotype 2/3 patients. Similarly, genotype 1 patients benefit from 48 weeks of therapy, while 24 weeks is sufficient for genotype 2/3 disease.
Recent data suggest treatment success is dependent on cumulative ribavirin exposure, as patients who receive <60% of the planned dose have lower response rates, regardless of whether reductions are from temporary interruptions or premature cessation of therapy. All patients should be monitored for hemolytic anemia, as early diagnosis allows management through small dose reductions and stepwise return to the target dose, maximizing cumulative exposure. Despite these recent advances in our knowledge, many questions remain, such as whether the role of ribavirin will change or even be eliminated as new therapies are developed.
Forewarned is forearmed
(2009)
Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma
(2022)
The prognostic role of platelet count in hepatocellular carcinoma (HCC) remains unclear, and in fact both thrombocytopenia and thrombocytosis are reported as predictors of unfavourable outcomes. This study aimed to clarify the prognostic value of preoperative platelet count in potentially resectable HCC. We retrospectively reviewed 128 patients who underwent hepatic resection for HCC at a tertiary academic centre (2007–2019). Patient data were modelled by regression analysis, and platelet count was treated as a continuous variable. 89 patients had BCLC 0/A tumours and 39 had BCLC B tumours. Platelet count was higher in patients with larger tumours and lower in patients with higher MELD scores, advanced fibrosis, and portal hypertension (p < 0.001 for all listed variables). After adjusting for BCLC stage and tumour diameter, low platelet count associated with reduced overall survival (hazard ratio 1.25 per 50/nL decrease in platelet count, 95% confidence interval (CI) 1.02–1.53, p = 0.034) and increased perioperative mortality (odds ratio 1.96 per 50/nL decrease in platelet count, 95% CI 1.19–3.53, p = 0.014). Overall, low platelet count correlates with increased liver disease severity, inferior survival, and excess perioperative mortality in resectable HCC. These insights might be applied in clinical practice to better select patients for resection.
Background: Cirrhosis is known to have a high prevalence and mortality worldwide. However, in Europe, the epidemiology of cirrhosis is possibly undergoing demographic changes, and etiologies may have changed due to improvements in standard of care. The aim of this population-based study was to analyze the trends and the course of liver cirrhosis and its complications in recent years in Germany.
Methods: We analyzed the data of all hospital admissions in Germany within diagnosis-related groups from 2005 to 2018. The diagnostic records of cirrhosis and other categories of diseases were based on ICD-10-GM codes. The primary outcome measurement was in-hospital mortality. Trends were analyzed through Poisson regression of annual number of admissions. The impact of cirrhosis on overall in-hospital mortality were assessed through the multivariate multilevel logistic regression model adjusted for age, sex, and comorbidities.
Findings: Of the 248,085,936 admissions recorded between 2005 and 2018, a total of 2,302,171(0•94%) were admitted with the diagnosis of cirrhosis, mainly as a comorbidity. Compared with other chronic diseases, patients admitted with cirrhosis were younger, mainly male and had the highest in-hospital mortality rate. Diagnosis of cirrhosis was an independent risk factor of in-hospital mortality with the highest odds ratio (OR:6•2[95%CI:6.1-6•3]) among all diagnoses. The prevalence of non-alcoholic fatty liver disease has increased four times from 2005 to 2018, while alcoholic cirrhosis is 20 times than other etiologies. Bleeding was found to be decreasing over time, but ascites remained the most common complication and was increasing.
Interpretation: This nationwide study demonstrates that cirrhosis represents a considerable healthcare burden, as shown by the increasing in-hospital mortality, also in combination with other chronic diseases. Alcohol-related cirrhosis and complications are on the rise. More resources and better management strategies are warranted.
In PC12 cells, a well studied model for neuronal differentiation, an elevation in the intracellular cAMP level increases cell survival, stimulates neurite outgrowth, and causes activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2). Here we show that an increase in the intracellular cAMP concentration induces tyrosine phosphorylation of two receptor tyrosine kinases, i.e. the epidermal growth factor (EGF) receptor and the high affinity receptor for nerve growth factor (NGF), also termed Trk(A). cAMP-induced tyrosine phosphorylation of the EGF receptor is rapid and correlates with ERK1/2 activation. It occurs also in Panc-1, but not in human mesangial cells. cAMP-induced tyrosine phosphorylation of the NGF receptor is slower and correlates with Akt activation. Inhibition of EGF receptor tyrosine phosphorylation, but not of the NGF receptor, reduces cAMP-induced neurite outgrowth. Expression of dominant-negative Akt does not abolish cAMP-induced survival in serum-free media, but increases cAMP-induced ERK1/2 activation and neurite outgrowth. Together, our results demonstrate that cAMP induces dual signaling in PC12 cells: transactivation of the EGF receptor triggering the ERK1/2 pathway and neurite outgrowth; and transactivation of the NGF receptor promoting Akt activation and thereby modulating ERK1/2 activation and neurite outgrowth.
Erratum in: Correction: Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells. Journal of biological chemistry 2020 Oct 23;295(43):14792. doi: 10.1074/jbc.AAC120.016177.
Background: Liver cirrhosis is associated with profound immunodysfunction, i.e. a parallel presence of chronic systemic inflammation and immunosuppression, which can result in acute-on-chronic liver failure (ACLF). Omega-3 fatty acids are precursors of pro-resolving mediators and support the resolution of inflammation.
Objective: The aim of this study was to determine plasma levels of omega-3 fatty acids in patients with liver cirrhosis and ACLF.
Methods: Patients with liver cirrhosis with and without ACLF were enrolled in a prospective cohort study and analyzed post-hoc for the present sub-study. Clinical data and biomaterials were collected at baseline and at day 7, 28 and after 3 months of follow-up. Plasma concentrations of arachidonic acid (ARA) and docosahexaenoic acid (DHA), which represent key omega-6 and -3 fatty acids, respectively, were quantified and associated with markers of systemic inflammation and severity of liver cirrhosis.
Results: A total of 117 patients were included in the present analyses. Of those, 26 (22.2%), 51 (43.6%) and 40 (34.2%) patients had compensated or decompensated liver cirrhosis, and ACLF. Plasma levels of ARA and DHA were similar in patients with compensated cirrhosis, decompensated cirrhosis, and ACLF. Furthermore, no significant association between plasma ARA or DHA and C-reactive protein or peripheral blood leukocytes were observed (P>0.05).
Conclusion: In our study plasma levels of key omega-3 and omega-6 fatty acid are neither associated with the severity of liver cirrhosis nor with liver-cirrhosis-associated systemic inflammation.
Three AKT serine/threonine kinase isoforms (AKT1/AKT2/AKT3) mediate proliferation, metabolism, differentiation and anti-apoptotic signals. AKT isoforms are activated down- stream of PI3-kinase and also by PI3-kinase independent mechanisms. Mutations in the lipid phosphatase PTEN and PI3-kinase that increase PIP3 levels increase AKT signaling in a large proportion of human cancers. AKT and other AGC kinases possess a regulatory mechanism that relies on a conserved hydrophobic motif (HM) C-terminal to the catalytic core. In AKT, the HM is contiguous to the serine 473 and two other newly discovered (serine 477 and tyrosine 479) regulatory phosphorylation sites. In AKT genes, this regulatory HM region is encoded in the final exon. We identified a splice variant of AKT2 (AKT2-13a), which contains an alternative final exon and lacks the HM regulatory site. We validated the presence of mRNA for this AKT2-13a splice variant in different tissues, and the presence of AKT2-13a protein in extracts from HEK293 cells. When overexpressed in HEK293 cells, AKT2-13a is phosphorylated at the activation loop and at the zipper/turn motif phosphoryla- tion sites but has reduced specific activity. Analysis of the human transcriptome correspond- ing to other AGC kinases revealed that all three AKT isoforms express alternative transcripts lacking the HM regulatory motif, which was not the case for SGK1-3, S6K1-2, and classical, novel and atypical PKC isoforms. The transcripts of splice variants of Akt1-3 excluding the HM regulatory region could lead to expression of deregulated forms of AKT.
Allostery is a phenomenon observed in many proteins where binding of a macromolecular partner or a small-molecule ligand at one location leads to specific perturbations at a site not in direct contact with the region where the binding occurs. The list of proteins under allosteric regulation includes AGC protein kinases. AGC kinases have a conserved allosteric site, the phosphoinositide-dependent protein kinase 1 (PDK1)-interacting fragment (PIF) pocket, which regulates protein ATP-binding, activity, and interaction with substrates. In this study, we identify small molecules that bind to the ATP-binding site and affect the PIF pocket of AGC kinase family members, PDK1 and Aurora kinase. We describe the mechanistic details and show that although PDK1 and Aurora kinase inhibitors bind to the conserved ATP-binding site, they differentially modulate physiological interactions at the PIF-pocket site. Our work outlines a strategy for developing bidirectional small-molecule allosteric modulators of protein kinases and other signaling proteins.
Background: MicroRNAs circulating in the blood, stabilized by complexation with proteins and/or additionally by encapsulation in lipid vesicles, are currently being evaluated as biomarkers. The consequences of their differential association with lipids/vesicles for their stability and use as biomarkers are largely unexplored and are subject of the present study.
Methods: The levels of a set of selected microRNAs were determined by quantitative reverse-transcription PCR after extraction from sera or vesicle- and non-vesicle fractions prepared from sera. The stability of these microRNAs after incubation with RNase A or RNase inhibitor, an inhibitor of RNase A family enzymes was studied.
Results: The levels of microRNA-1 and microRNA-122, but not those of microRNA-16, microRNA-21 and microRNA-142-3p, declined significantly during a 5-h incubation of the sera. RNase inhibitor prevented the loss of microRNAs in serum as well as the degradation of microRNA-122, a microRNA not expressed in blood cells, in whole blood. Stabilization of microRNA-122 was also achieved by hemolysis. Prolonged incubation of the sera led to enrichment of vesicle-associated relative to non-vesicle-associated microRNAs. Vesicle-associated microRNAs were more resistant to RNase A treatment than the respective microRNAs not associated with vesicles.
Conclusions: Serum microRNAs showed differential stability upon prolonged incubation. RNase inhibitor might be useful to robustly preserve the pattern of cell-free circulating microRNAs. In the case of microRNAs not expressed in blood cells this can also be achieved by hemolysis. Vesicle-associated microRNAs appeared to be more stable than those not associated with vesicles, which might be useful to disclose additional biomarker properties of miRNAs.
Purpose: The purpose of the study is to retrospectively evaluate the development and technological progress in local oncological treatments of hepatocellular carcinoma (HCC) by means of ablation techniques like laser interstitial thermal therapy (LITT), microwave ablation (MWA) and transarterial chemoembolization (TACE) in a multimodal application.
Method: This retrospective single-center study uses data generated between 1993 and 2020 (1,045 patients). Therapy results are evaluated using survival rates of Kaplan-Meier estimator, Cox proportional hazard regression and log-rank test.
Results: Median survival times in group LITT (25 patients) are 1.6 years, and, 2.6 years for LITT + TACE (67 patients). For LITT only treatments 1-/3-/5-year survival rates scored 64%, 24% and 20%. Results for combined LITT + TACE treatments were 84%, 37% and 14%. Median survival time in group MWA (227 patients) is 4.5 years. Estimated median survival time for MWA + TACE (108 patients) leads to a median survival time of 2.7 years. In group MWA the 1-/3-/5-year survival rates are 85%, 54%, 45%. Group MWA + TACE shows values of 79%, 41% and 25%. A separate group of 618 patients has been analyzed with TACE as monotherapy. Median survival time of 1 year was estimated in this group. 1-/3-/5-year survival rates are 48%, 15% and 8%. - Cox regression analysis showed that the different treatment methods are statistically significant predictors for survival of patients.
Conclusions: Treatments with MWA resulted in best median survival rates, followed by MWA + TACE in combination. Survival rates of MWA only are significantly higher vs. LITT, vs. LITT + TACE and vs. TACE monotherapy.
Background: The aim of this meta-analysis was to evaluate efficacy and safety of first-line chemotherapy with or without a monoclonal antibody in elderly patients ( ≥ 70 years) with metastatic colorectal cancer (mCRC), since they are frequently underrepresented in clinical trials.
Results: Individual data from 10 studies were included. From a total of 3271 patients, 604 patients (18%) were ≥ 70 years (median 73 years, range 70–88). Of these, 335 patients were treated with a bevacizumab-based first-line regimen and 265 were treated with chemotherapy only. The median PFS was 8.2 vs. 6.5 months and the median OS was 16.7 vs. 13.0 months in patients treated with and without bevacizumab, respectively. The safety profile of bevacizumab in combination with first-line chemotherapy did not differ from published clinical trials.
Materials and Methods: PubMed and Cochrane Library searches were performed on 29 April 2013 and studies published to this date were included. Authors were contacted to request progression-free survival (PFS), overall survival (OS) data, patient data on treatment regimens, age, sex and potential signs of toxicity in patients ≥ 70 years of age.
Conclusions: This meta-analysis suggests that the addition of bevacizumab to standard first-line chemotherapy improves clinical outcome in elderly patients with mCRC and is well tolerated.
The nuclear factor kappa beta (NFκB) signaling pathway plays an important role in liver homeostasis and cancer development. Tax1-binding protein 1 (Tax1BP1) is a regulator of the NFκB signaling pathway, but its role in the liver and hepatocellular carcinoma (HCC) is presently unknown. Here we investigated the role of Tax1BP1 in liver cells and murine models of HCC and liver fibrosis. We applied the diethylnitrosamine (DEN) model of experimental hepatocarcinogenesis in Tax1BP1+/+ and Tax1BP1−/− mice. The amount and subsets of non-parenchymal liver cells in in Tax1BP1+/+ and Tax1BP1−/− mice were determined and activation of NFκB and stress induced signaling pathways were assessed. Differential expression of mRNA and miRNA was determined. Tax1BP1−/− mice showed increased numbers of inflammatory cells in the liver. Furthermore, a sustained activation of the NFκB signaling pathway was found in hepatocytes as well as increased transcription of proinflammatory cytokines in isolated Kupffer cells from Tax1BP1−/− mice. Several differentially expressed mRNAs and miRNAs in livers of Tax1BP1−/− mice were found, which are regulators of inflammation or are involved in cancer development or progression. Furthermore, Tax1BP1−/− mice developed more HCCs than their Tax1BP1+/+ littermates. We conclude that Tax1BP1 protects from liver cancer development by limiting proinflammatory signaling.